FHTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

FH

Mkt Cap

$110.2M

Volume

899.63K

Next Earnings

November 4th

Loading chart

FH

FHTXFoghorn Therapeutics Inc. Common Stock

FHTX

Pay with—

Available Balance0.00

FH

Mkt Cap

$112.2M

Volume

899.63K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Step Pharma announces the appointment of Neil Gallagher as Non-Executive DirectorStep Pharma appoints Neil J. Gallagher, MD, PhD as Non-Executive Director to strengthen its board as it advances dencatistat, a first-in-class CTPS1 inhibitor, across three clinical programmes for essential thrombocythaemia, lymphoma, and solid tumours. Gallagher brings over 25 years of clinical development experience from senior roles at major pharmaceutical companies including Amgen, AstraZeneca, Novartis, and AbbVie.GlobeNewswire Inc. · Jul 1, 2026

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual MeetingFoghorn Therapeutics announced it will present multiple oral and poster presentations at the 2026 AACR Annual Meeting in San Diego. The company will showcase new preclinical data for FHD-909 (LY4050784), a selective SMARCA2 inhibitor developed with Eli Lilly for SMARCA4-mutant cancers, including potential combination opportunities with anti-PD-1 antibodies. Additional presentations will highlight preclinical progress on selective CBP, EP300, and ARID1B degrader programs targeting various cancer types.GlobeNewswire Inc. · Apr 9, 2026

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent CliffThe precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep development in gastrointestinal cancers; Nurix is executing pivotal studies for its BTK degrader bexobrutideg in chronic lymphocytic leukemia; Erasca reported early clinical data for its pan-RAS molecular glue ERAS-0015; Foghorn raised $50 million for its SMARCA4-targeting program; and ORIC presented strong Phase 1b data for rinzimetostat in prostate cancer.Benzinga · Jan 14, 2026

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026Foghorn Therapeutics raised $50 million in equity financing from BVF Partners, Deerfield Management, Flagship Pioneering, and a biotech mutual fund. The company reported progress on its Phase 1 trial of FHD-909 (partnered with Eli Lilly) for SMARCA4-mutant cancers, with selective CBP and EP300 degrader programs advancing toward IND filings in 2026. The company maintains a strong balance sheet of $208.9 million, extending cash runway into the first half of 2028.GlobeNewswire Inc. · Jan 10, 2026

4DMT Appoints Kristian Humer as Chief Financial Officer4D Molecular Therapeutics announced the appointment of Kristian Humer as Chief Financial Officer, bringing over two decades of finance and biotechnology experience to support the company's late-stage clinical development and commercial planning.GlobeNewswire Inc. · Nov 17, 2025

Foghorn Therapeutics to Participate in Three Upcoming Investor ConferencesFoghorn Therapeutics, a clinical-stage biotechnology company, announced participation in upcoming healthcare conferences and provided an update on its Phase 1 dose escalation trial for FHD-909 targeting SMARCA4 mutated cancers.GlobeNewswire Inc. · Aug 27, 2025

Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate UpdateFoghorn Therapeutics reports progress on its oncology drug development pipeline, including the FHD-909 Phase 1 trial for SMARCA4 mutated cancers and advancing selective degrader programs targeting CBP, EP300, and ARID1B, with a strong cash position of $198.7 million through 2028.GlobeNewswire Inc. · Aug 5, 2025

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of DirectorsFoghorn Therapeutics, a clinical-stage biotechnology company, announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty to its Board of Directors. The new board members bring extensive experience in the biotechnology industry and will provide strategic insights to help advance Foghorn's pipeline.GlobeNewswire Inc. · May 1, 2025

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual MeetingFoghorn Therapeutics will host a virtual investor event on April 29, 2025, to review updates on its pipeline, including new preclinical data for its selective SMARCA2 inhibitor FHD-909 and its selective CBP and EP300 degrader programs.GlobeNewswire Inc. · Apr 15, 2025

Foghorn Therapeutics to Participate in the BMO Oncology SummitFoghorn Therapeutics, a clinical-stage biotechnology company, announced its participation in investor meetings at the BMO Oncology Summit. The company's Gene Traffic Control platform and pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases, with an initial focus on oncology.GlobeNewswire Inc. · Oct 1, 2024

to start trading

FH

FHTXFoghorn Therapeutics Inc. Common Stock

FHTX

Pay with—

Available Balance0.00

Your PositionYou don't own any FHTX yet.

Related Tickers

Earnings